Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.67 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.67 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15778295 | 0.93 | AKT1 (0.58) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL17897755 | 0.92 | AKT1 (0.80) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL15777209 | 0.90 | AKT1 (0.83) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL15778899 | 0.89 | AKT1 (0.66) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL28897000 | 0.87 | RAB9A (0.57) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL17897767 | 0.86 | AKT1 (0.68) | AKT1PDPK1CYTH3ALDH1A1MEN1 | |
| SCHEMBL17897750 | 0.85 | PDPK1 (0.71) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL15777853 | 0.84 | AKT1 (0.71) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL17897766 | 0.83 | AKT1 (0.64) | AKT1PDPK1CYTH3RAB9ANPC1 | |
| SCHEMBL28437415 | 0.83 | PDPK1 (0.68) | AKT1PDPK1CYTH3RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194279-A1 | ONE POT PROCESS FOR THE CONVERSION OF AROYL CHLORIDES TO ACYL THIOUREAS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-07 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194279-A1 | ONE POT PROCESS FOR THE CONVERSION OF AROYL CHLORIDES TO ACYL THIOUREAS | TRRAP, NAT1, AHR | AKT1 2603/4885PDPK1 4430/4885CYTH3 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.